Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 13:2020:9186274.
doi: 10.1155/2020/9186274. eCollection 2020.

Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature

Justyna Szczęch  1 , Dominik Samotij  1 , Kamila Jaworecka  1 , Aleksandra Tobiasz  2 , Adam Reich  1
Affiliations
Review

Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature

Justyna Szczęch et al. Biomed Res Int. .

Abstract

Objective: The aim of the study was to evaluate QoL in patients suffering from morphea. Material and Methods. Sixty-five patients with morphea were recruited into this cross-sectional, prospective parallel study. QoL among adult patients was assessed with the Dermatology Life Quality Index (DLQI) and Euro-QoL-5D questionnaire; patients aged <17 years used the Children's Dermatology Life Quality Index (CDLQI). The severity of morphea was assessed using the Localized Scleroderma Cutaneous Assessment Tool. The results of QoL and its association with disease severity were compared between patients with various morphea subtypes.

Results: The mean DLQI scoring was 3.8 ± 4.1 points and the CDLQI was 2.3 ± 3.0. The mean value of Visual Analogue Scale thermometer (EQ VAS) was 66.9 ± 17.5 points. The disease activity of morphea based on mLoSSI correlated significantly with QoL impairment according to the DLQI (R = 0.41, p = 0.001). No significant correlation was observed between morphea-induced damage and QoL (p = 0.99).

Conclusions: Evaluation of QoL in patients with morphea is still challenging due to lack of good assessment tools dedicated specifically for morphea patients. In general, QoL in morphea patients is significantly correlated with the disease activity, but not with disease-induced skin damage.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Classification of morphea intensity/severity [10].
Figure 2
Figure 2
Morphea activity and scoring of the Dermatology Life Quality Index (DLQI).
See this image and copyright information in PMC

References

    1. Tuffanelli D. L. Localized scleroderma. Seminars in Cutaneous Medicine and Surgery. 1998;17(1):27–33. doi: 10.1016/s1085-5629(98)80059-x. - DOI - PubMed
    1. Fett N., Werth V. P. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. Journal of the American Academy of Dermatology. 2011;64(2):217–228. - PubMed
    1. Careta M. F., Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. Anais Brasileiros de Dermatologia. 2015;90(1):62–73. doi: 10.1590/abd1806-4841.20152890. - DOI - PMC - PubMed
    1. Knobler R., Moinzadeh P., Hunzelmann N., et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology. 2017;31(9):1401–1424. doi: 10.1111/jdv.14458. - DOI - PubMed
    1. Herédi E., Rencz F., Balogh O., et al. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics. 2014;15(Supplement 1):111–119. doi: 10.1007/s10198-014-0600-x. - DOI - PubMed